英国糖尿病缓解临床试验(DiRECT)持续支持减重维持的5年随访:一项扩展研究
DiRECT试验将149例干预组和149例对照组2型糖尿病患者随机分组,干预组接受减重管理,2年后101例中95例进入扩展组接受低强度饮食支持至5年。5年时扩展组平均减重6.1 kg,13%处于缓解,扩展组与未扩展组相比更多访视达到HbA1c<48 mmol/mol、未用降糖药和处于缓解,严重不良事件少于对照组。
要点
- 5年时扩展组平均减重6.1 kg,85例中11例(13%)处于糖尿病缓解。
- 扩展组较未扩展组更多访视达到HbA1c<48 mmol/mol(36% vs 17%)、未用降糖药(62% vs 30%)和缓解(34% vs 12%)。
- 原干预组严重不良事件4.8例/100患者年,低于对照组的10.2例/100患者年(p=0.0080)。
核心结论
- 扩展的DiRECT干预与更大的累积和绝对减重相关,并提示5年内健康状况改善。
研究设计与样本
- DiRECT为在英国基层诊所开展的随机对照有效性试验,参与者为20-65岁、2型糖尿病病程小于6年、BMI大于27 kg/m2且未使用胰岛素者。
- 干预包括停用降糖和降压药、全饮食替代(825-853 kcal/天配方饮食12-20周)、逐步食物再引入(2-8周)及结构化减重维持支持。
- 2年后向仍在试验的101例干预参与者提供低强度支持3年,95例(94%)同意进入扩展组,54例分配至非扩展组(撤销干预)。
- 5年时从剩余干预参与者、退出干预者及原随机分组中每年收集英国国家医疗服务体系数据。
- 主要结局为2型糖尿病缓解;试验注册号ISRCTN 03267836。
主要发现
- 5年时DiRECT扩展组参与者(n=85)平均减重6.1 kg,85例中11例(13%)处于缓解。
- 与未扩展组相比,扩展组更多访视达到HbA1c<48 mmol/mol(<6.5%;36% vs 17%,p=0.0004)、未用降糖药(62% vs 30%,p<0.0001)和处于缓解(34% vs 12%,p<0.0001)。
- 原对照组参与者(n=149)平均减重4.6 kg(n=82),93例中5例(5%)处于缓解。
- 与原对照组相比,原干预组更多访视体重低于基线超过5%(61% vs 29%,p<0.0001)、HbA1c低于48 mmol/mol(29% vs 15%,p=0.0002)、未用降糖药(51% vs 16%,p<0.0001)和处于缓解(27% vs 4%,p<0.0001)。
- 2年时处于缓解者中,26%在5年时仍处于缓解;原干预组严重不良事件为4.8例/100患者年,低于对照组的10.2例/100患者年(p=0.0080)。
临床怎么用
- 原文结论为扩展的DiRECT干预与更大的累积和绝对减重相关,并提示5年内健康状况改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In DiRECT, a randomised controlled effectiveness trial, weight management intervention after 2 years resulted in mean weight loss of 7·6 kg, with 36% of participants in remission of type 2 diabetes. Of 36 in the intervention group who maintained over 10 kg weight loss at 2 years, 29 (81%) were in remission. Continued low-intensity dietary support was then offered up to 5 years from baseline to intervention participants, aiming to maintain weight loss and gain clinical benefits. This extension study was designed to provide observed outcomes at 5 years. METHODS: The DiRECT trial took place in primary care practices in the UK. Participants were individuals aged 20-65 years who had less than 6 years' duration of type 2 diabetes, a BMI greater than 27 kg/m2, and were not on insulin. The intervention consisted of withdrawal of antidiabetic and antihypertensive drugs, total diet replacement (825-853 kcal per day formula diet for 12-20 weeks), stepped food reintroduction (2-8 weeks), and then structured support for weight-loss maintenance. After sharing the 2-year results with all participants, UK National Health Service data were collected annually until year 5 from remaining intervention participants who received low-intensity dietary support, intervention withdrawals, and the original randomly allocated groups. The primary outcome was remission of type 2 diabetes; having established in the DiRECT trial that sustained weight loss was the dominant driver of remission, this was assumed for the Extension study. The trial is registered with the ISRCTN registry, number 03267836. FINDINGS: Between July 25, 2014, and Aug 5, 2016, 149 participants were randomly assigned to the intervention group and 149 were assigned to the control group in the original DiRECT study. After 2 years, all intervention participants still in the trial (101 [68%] of 149) were approached to receive low-intensity support for a further 3 years. 95 (94%) of 101 were able to continue and consented and were allocated to the DiRECT extension group. 54 participants were allocated to the non-extension group, where intervention was withdrawn. At 5 years, DiRECT extension participants (n=85) lost an average of 6·1 kg, with 11 (13%) of 85 in remission. Compared with the non-extension group, DiRECT extension participants had more visits with HbA1c <48 mmol/mol (<6·5%; 36% vs 17%, p=0·0004), without glucose-lowering medication (62% vs 30%, p<0·0001), and in remission (34% vs 12%, p<0·0001). Original control participants (n=149) had mean weight loss 4·6 kg (n=82), and 5 (5%) of 93 were in remission. Compared with control participants, original intervention participants had more visits with weight more than 5% below baseline (61% vs 29%, p<0·0001), HbA1c below 48 mmol/mol (29% vs 15%, p=0·0002), without antidiabetic medication (51% vs 16%, p<0·0001), and in remission (27% vs 4%, p<0·0001). Of those in remission at year 2, 26% remained in remission at 5 years. Serious adverse events in the original intervention group (4·8 events per 100 patient-years) were under half those in the control group (10·2 per 100 patient-years, p=0·0080). INTERPRETATION: The extended DiRECT intervention was associated with greater aggregated and absolute weight loss, and suggested improved health status over 5 years. FUNDING: Diabetes UK.
引用
- Lean ME, Leslie WS, Barnes AC, et al. 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study. Lancet Diabetes Endocrinol. 2024. PMID: 38423026. doi:10.1016/S2213-8587(23)00385-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。